Clinical Sessions for Recertification (CE)
Educational Sessions (CE)
Planned in cooperation with the American College of Clinical Pharmacy
ACPE Activity #0217-9999-19-160-L01-P
2.00 Contact Hours | Application-based
Arthur Allen, Pharm.D., CACP
Anticogulation Program Manager
VA Salt Lake City Healthcare System
Salt Lake City, UT
Anticoagulation Forum: Member - Board of Directors (Status: Ongoing); Janssen Pharmaceuticals: Speaker's Bureau (Status: Ongoing); Portola Pharmaceuticals: Speaker's Bureau (Status: Ongoing); Thrombosis and Hemostasis Societies of North America: Member - Board of Directors (Status: Ongoing)
This session is focused on patients with active cancer and their increased risk of thromboembolism, bleeding complications, medication-related adverse events, and drug-drug interactions. Most specifically this session will focus on what is new in the prevention and treatment of primary venous thromboembolism (VTE) in patients with cancer. Included in this session will be a discussion of the use of direct oral anticoagulants (DOACs) in this patient population and how new evidence in both efficacy and safety data may be causing a shift in the care of patients.
This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.